Printer Friendly

Molecular devices acquires Universal Imaging. (News, Trends & Market Intelligence for Instrument Executives).

Sunnyvale, CA 6/3/02--Molecular Devices has purchased Universal Imaging Corp. (UIC) for $22 million in cash. UIC, formed in 1983, develops and sells automated cellular imaging and screening systems for biological and industrial imaging applications. UIC employs 52 people, with revenue totaling $9.6 million in 2001. Molecular Devices stated that the acquisition will expand its offering of tools for cell analysis. Molecular Devices estimates that the acquisition will contribute $6-$7 million in sales for the rest of 2002 and will be accretive to earnings per share in 2003.

This acquisition fits with Molecular Devices' current product line and allows it to capitalize on applications for cell analysis and imaging. The price paid in relation to sales reflects the demand for these techniques that are expected to be integral in proteomics research. Molecular Devices reports that UIC is profitable on an operating basis.
COPYRIGHT 2002 Strategic Directions International Inc. (SDI)
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Instrument Business Outlook
Article Type:Brief Article
Geographic Code:1USA
Date:Jun 15, 2002
Previous Article:Thermo makes two acquisitions. (News, Trends & Market Intelligence for Instrument Executives).
Next Article:Celera reorganizes and lays off staff. (News, Trends & Market Intelligence for Instrument Executives).

Related Articles
Society for Neuroscience: 28th Annual Meeting.
Random Samples.
Cell-based imaging: companies take notice.
Molecular Devices and Caliper reach settlement.
Molecular Devices to buy Axon Instruments for $140 million.
2004 acquisitions keep instrument companies busy.
Molecular devices purchases Transfluor imaging technology.
Instrumentation and cell-based assays.
Molecular devices lowers third quarter guidance.
2007 mergers & acquisitions review.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters